Skip to content

Frequently asked questions

Here are short answers to the questions people ask most about GLP-1 medicines: units and milligrams, doses, fills, cost and coverage. Each answer comes from the same label, price and policy records as the rest of the site. The longer guides linked below show the sources.

Nothing here is medical advice. For your own dose, your prescriber and the pharmacy label decide.

Calculators

Guides

Still have a question?

We can’t answer questions about your own treatment, dose or symptoms. Please ask your prescriber or pharmacist. For anything about the site itself, use the contact page. In an emergency call 911, and for a suspected overdose call Poison Help at 1-800-222-1222.

Frequently asked questions

How many units is a dose of semaglutide or tirzepatide?

It depends on your vial, so there is no single answer. A unit is a volume marking on an insulin syringe. FDA says the volume a unit dose represents may vary depending on the product's concentration, which differs between compounders, the pharmacies that mix these products. To find units, divide the dose in mg by the vial strength in mg per mL, then multiply by 100. Ask your pharmacist to confirm your dose in milligrams and milliliters.

What does a unit on a syringe mean?

On a U-100 insulin syringe, 100 units is 1 mL, so one unit is 0.01 mL of liquid. A unit measures liquid, not medicine. How many mg are in each unit depends on the strength printed on the vial. Our guide to reading a U-100 syringe walks through the math.

How do I convert units to mg?

Divide the units by 100 to get mL, then multiply by the vial strength in mg per mL. For example, 20 units is 0.2 mL, and 0.2 mL of a 2.5 mg per mL vial holds 0.5 mg. The units to mg calculator does the same math for the strength you enter. It does not recommend a dose.

Do the dosage calculators work for pens?

You don't need them for pens. A pen measures the dose for you in mg, so there is nothing to convert. FDA says the approved injectable semaglutide products are dosed in milligrams and have standard concentrations. The unit calculators are for a dose you draw from a vial with a U-100 syringe. There, the strength on the vial label decides the number of units.

What is the starting dose of each GLP-1?

It depends on the medicine. On their labels, Zepbound and Mounjaro start at 2.5 mg once weekly, Wegovy injection and Ozempic injection at 0.25 mg once weekly, Trulicity at 0.75 mg once weekly, Foundayo at 0.8 mg once daily, Wegovy tablets and Ozempic tablets at 1.5 mg once daily, Rybelsus at 3 mg once daily and Saxenda at 0.6 mg once daily. Your prescriber decides your dose.

How often does a GLP-1 dose increase?

The labels set a minimum time at each step. For the weekly injections it is 4 weeks. For Foundayo, Wegovy tablets, Ozempic tablets and Rybelsus it is 30 days. Saxenda steps up each week for the first four weeks. The minimum is the earliest a step can happen, and your prescriber decides whether it does.

What should I do after a missed dose?

Each label has its own rule for how late you can take a missed dose, and the rules differ between medicines. The missed dose calculator applies the rule for your medicine to your dates. That rule is a starting point. Your prescriber or pharmacist has the final say, especially after more than one missed dose.

How much weight do people lose in the label trials?

The Zepbound label reports average body-weight changes of 15.0%, 19.5% and 20.9% at 72 weeks on 5 mg, 10 mg and 15 mg in Study 1, in adults without diabetes, against 3.1% with placebo. The Wegovy label reports 14.9% at 68 weeks on 2.4 mg in Study 2, against 2.4% with placebo. These are averages from separate trials, not a prediction for one person.

Why is a year of a weekly GLP-1 13 fills and not 12?

Because a fill, the pack you get from the pharmacy, holds four doses of a weekly injection. That is a 28-day supply, not a calendar month. Thirteen fills of 28 days cover 364 days, while twelve cover only 336. Daily tablets such as Foundayo and the Wegovy pill come as a 30-day supply, which makes twelve fills a year.

Does insurance cover GLP-1 medicines?

It depends on your plan and your employer. In the published policies of 11 payers (insurers and other groups that pay for care), Wegovy and Zepbound are covered for weight loss only where the plan or employer includes that benefit, and almost always with prior authorization, meaning the plan must approve it before it pays. Ozempic and Mounjaro are covered for type 2 diabetes. Your own plan document decides.

Does Medicare cover GLP-1 medicines?

Medicare Part D does not cover drugs used for weight loss, but it can cover GLP-1s for type 2 diabetes, cardiovascular risk reduction, sleep apnea and MASH. From July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge lets eligible Part D enrollees get Wegovy, Foundayo or the Zepbound KwikPen for weight management at a $50 copay per one-month supply, according to CMS.

Can I use a savings card with Medicare or Medicaid?

No. The Lilly and Novo Nordisk savings cards are for people with commercial (private or employer) drug insurance. If you are enrolled in Medicare, Medicaid, TRICARE, VA or another government program, you are excluded.

Where do the prices on this site come from?

Only from primary sources, meaning the original pages: the manufacturers' own pages (Lilly, LillyDirect, Novo Nordisk, NovoCare), government pages (TrumpRx.gov, Medicare.gov, CMS.gov) and each telehealth provider's own pricing page. We keep each price as one record with an exact quote from its source, and the link to that source appears beside the number. Prices can change, so confirm the amount before you pay.

Does glp1doses tell me what dose to take?

No. We report what the FDA labels and published price sources say, and we do the math on those numbers. We do not give individual medical advice or suggest doses beyond what the label states. Dosing decisions belong with your prescriber, and the pharmacy label on your medicine is the one to follow.

Sources (3)

  1. 1.
    Zepbound prescribing information, section 14.1, Table 2 (DailyMed)
    “Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight. % Change from baseline: Study 1 Placebo N = 643: -3.1; Study 1 ZEPBOUND 5 mg N = 630: -15.0; Study 1 ZEPBOUND 10 mg N = 636: -19.5; Study 1 ZEPBOUND 15 mg N = 630: -20.9; Study 2 Placebo N = 315: -3.2; Study 2 ZEPBOUND 10 mg N = 312: -12.8; Study 2 ZEPBOUND 15 mg N = 311: -14.7”
  2. 2.
    Wegovy prescribing information, section 14.2, Table 8 (DailyMed)
    “After 68 weeks, treatment with WEGOVY injection resulted in a statistically significant reduction in body weight compared with placebo. Greater proportions of patients treated with WEGOVY injection achieved 5%, 10% and 15% weight loss than those treated with placebo as shown in Table 8.”
  3. 3.
    FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products
    “Additionally, the instructions that accompany the compounded drug, if provided, may instruct users to administer semaglutide injections in “units” (the volume of which may vary depending on the concentration), rather than milligrams or milliliters. FDA is aware of some instances in which patients have been given syringes that are significantly larger than the prescribed volume of semaglutide (see example in Figure 1).”